15:57:55 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-10-31 Kvartalsrapport 2024-Q3
2024-08-29 Kvartalsrapport 2024-Q2
2024-04-30 Ordinarie utdelning GENT 0.00 NOK
2024-04-30 Kvartalsrapport 2024-Q1
2024-04-29 Årsstämma 2024
2024-02-09 Bokslutskommuniké 2023
2023-10-26 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-05 Kvartalsrapport 2023-Q1
2023-05-05 Ordinarie utdelning GENT 0.00 NOK
2023-05-04 Årsstämma 2023
2023-02-16 Bokslutskommuniké 2022
2022-10-27 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-19 Ordinarie utdelning GENT 0.00 NOK
2022-05-18 Årsstämma 2022
2022-04-28 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2021-10-21 Kvartalsrapport 2021-Q3
2021-08-25 Kvartalsrapport 2021-Q2
2021-05-05 Ordinarie utdelning GENT 0.00 NOK
2021-05-04 Årsstämma 2021
2021-04-16 Kvartalsrapport 2021-Q1
2021-02-11 Bokslutskommuniké 2020
2020-10-29 Kvartalsrapport 2020-Q3
2020-08-21 Kvartalsrapport 2020-Q2
2020-05-15 Ordinarie utdelning GENT 0.00 NOK
2020-05-14 Årsstämma 2020
2020-04-24 Kvartalsrapport 2020-Q1
2020-02-14 Bokslutskommuniké 2019
2019-11-21 Extra Bolagsstämma 2019
2019-05-10 Ordinarie utdelning GENT 0.00 NOK
2018-07-13 Extra Bolagsstämma 2018
2018-06-13 Ordinarie utdelning GENT 0.00 NOK
2018-02-27 Bokslutskommuniké 2017
2017-06-06 Årsstämma 2017

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriBioteknik
Gentian Diagnostics är ett norskt bolag som utvecklar olika produkter inom hälsovård. Exempel är diagnostiska test med målet att utveckla och effektivisera diagnostisk behandling, vilket innefattar behandling utav cancer och hjärt- och kärlsjukdomar. En stor del av verksamheten innefattar FoU utveckling. Bolaget grundades 1998 och har sitt huvudkontor i Moss, Norge.
2023-11-24 10:07:59
Moss, 24 November 2023

Reference is made to the annual general meeting 18 May 2022 where guidelines for
remuneration of executive personnel were approved. In accordance with these
guidelines the board of Gentian Diagnostics ASA has allocated a total of 339,962
options to key employees under the existing option program.

The following number of options have been allocated to primary insiders of
Gentian Diagnostics ASA:

Hilja Ibert, Chief Executive Officer: 139,962 options. Following the allocations
Ms. Ibert holds 6,525 shares and 359,924 options.

Njaal Kind, Group Chief Financial Officer: 40,000 options. Following the
allocations Mr. Kind holds 26,125 shares and 180,670 options in the Company.

Markus Jaquemar, Chief Commercial Officer: 40,000 options. Following the
allocation Mr. Jaquemar holds 87,500 options in the Company.

Aleksandra Havelka, Chief Scientific Officer: 30,000 options. Following the
allocation Ms. Havelka hold 2,000 shares and 70,000 options in the Company.

Torsten Knüttel, Vice President R&D: 30,000 options. Following the allocation
Mr. Knüttel holds 1,125 shares and 70,000 options in the Company.

The exercise price for the options granted is NOK 40,71 being the being the
average volume-weighted share price on the Oslo Stock Exchange for the past 10
trading days prior to 24 November 2023. The right to exercise the options is
vested over a period of 2 years, with 50% of the options vesting by the end of
each year as follows: (i) 50% of the options granted, no earlier than 3 years
after the allocation date (ii) 50% of the options granted, no earlier than 4
years after the allocation date.

Attached are the notifications of the transactions pursuant to the market abuse
regulation article 19.
This information is subject to the disclosure requirements pursuant to Section
5-12 the Norwegian Securities Trading Act.

For further information, please contact:
Njaal Kind
CFO, Gentian Diagnostics ASA
E-mail: njaal.kind@gentian.no
Phone. +47 919 06 525